Valneva News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

19.12.24	Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India (GlobeNewswire)
05.12.24	VALNEVA - Declaration of shares and voting rights: November 30, 2024 (GlobeNewswire)
04.12.24	Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal (GlobeNewswire)
03.12.24	Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® (GlobeNewswire)
26.11.24	Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA (GlobeNewswire)
13.11.24	Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 (GlobeNewswire)
12.11.24	Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences (GlobeNewswire)
07.11.24	Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
06.11.24	VALNEVA - Declaration of shares and voting rights: October 31, 2024 (GlobeNewswire)
21.10.24	Valneva to Present on Chikungunya at Several Leading Scientific Conferences (GlobeNewswire)
16.10.24	Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V (GlobeNewswire)
10.10.24	Valneva Hosts Investor Day in New York City (GlobeNewswire)
04.10.24	Valneva SE - Declaration of shares and voting rights - September 30, 2024 (GlobeNewswire)
03.10.24	Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET (GlobeNewswire)
18.09.24	Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada (GlobeNewswire)
13.09.24	Valneva Announces the Success of its Private Placement Raising approximately €60 Million (GlobeNewswire)
12.09.24	Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros (GlobeNewswire)
04.09.24	VALNEVA - Declaration of shares and voting rights: August 31, 2024 (GlobeNewswire)
03.09.24	Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate (GlobeNewswire)
13.08.24	Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
06.08.24	VALNEVA - Declaration of shares and voting rights: July 31, 2024 (GlobeNewswire)
01.08.24	Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate (GlobeNewswire)
22.07.24	CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine (GlobeNewswire)
17.07.24	Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion (GlobeNewswire)
04.07.24	Declaration of shares and voting rights - Valneva SE - June 30, 2024 (GlobeNewswire)
01.07.24	Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ® (GlobeNewswire)
26.06.24	Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board (GlobeNewswire)
24.06.24	Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ® (GlobeNewswire)
05.06.24	Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update (GlobeNewswire)
04.06.24	VALNEVA - Declaration of shares and voting rights: May 31, 2024 (GlobeNewswire)
04.06.24	Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June (GlobeNewswire)
03.06.24	Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases (GlobeNewswire)
31.05.24	Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine (GlobeNewswire)
21.05.24	Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer (GlobeNewswire)
13.05.24	Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine (GlobeNewswire)
07.05.24	Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
06.05.24	Declaration of shares and voting rights April 30, 2024 - VALNEVA SE (GlobeNewswire)
04.04.24	Declaration of voting rights - Valneva SE, March 2024 (GlobeNewswire)
26.03.24	Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate (GlobeNewswire)
25.03.24	Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F (GlobeNewswire)
21.03.24	Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C. (GlobeNewswire)
20.03.24	Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook (GlobeNewswire)
18.03.24	Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed (GlobeNewswire)
06.03.24	VALNEVA Declaration of shares and voting rights - February 29, 2024 (GlobeNewswire)
04.03.24	Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences (GlobeNewswire)
29.02.24	U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ® (GlobeNewswire)
15.02.24	Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance (GlobeNewswire)
07.02.24	VALNEVA: Declaration of shares and voting rights - January 31, 2024 (GlobeNewswire)
05.02.24	Valneva Announces Sale of Priority Review Voucher for $103 Million (GlobeNewswire)
10.01.24	Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20.12.24		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
20.12.24		Handel in Europa: STOXX 50 schliesst im Minus
20.12.24		Minuszeichen in London: FTSE 100 schwächelt zum Ende des Freitagshandels
20.12.24		Dow Jones aktuell: Dow Jones fällt zum Start des Freitagshandels zurück
20.12.24		NASDAQ-Handel NASDAQ 100 schwächelt zum Start des Freitagshandels
20.12.24		Anleger in London halten sich zurück: So bewegt sich der FTSE 100 aktuell
20.12.24		Wechsel bei Sanofi: Ex-Morphosys-Chef Kress tritt in den Verwaltungsrat ein -Sanofi-Aktie tiefer

20.12.24

Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones

20.12.24

Handel in Europa: STOXX 50 schliesst im Minus

20.12.24

Minuszeichen in London: FTSE 100 schwächelt zum Ende des Freitagshandels

20.12.24

Dow Jones aktuell: Dow Jones fällt zum Start des Freitagshandels zurück

20.12.24

NASDAQ-Handel NASDAQ 100 schwächelt zum Start des Freitagshandels

20.12.24

Anleger in London halten sich zurück: So bewegt sich der FTSE 100 aktuell